Verified Nov 2026
Batteries & E-Mobility
·

Nutley, New Jersey
·
Since 1995
Eisai Inc. is the North American pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., founded in 1995 and headquartered in Nutley, New Jersey. The company employs over 2,000 people and generates an estimated $5–10 billion in annual revenue. It discovers, develops, and markets therapies focused on neurology and oncology, serving the automotive, electric-vehicle, medical, renewable-energy, and industrial-equipment sectors. In 2026, Eisai extended a neurodegenerative disease research partnership with University College London and committed $64 million to expand its UK manufacturing facility for injectable drug packaging.
Eisai at a glance
Revenue
$5-10B
Est. band
Employees
1,000-5,000
Founded
1995
Headquarters
Nutley, New Jersey
Import activity
37
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
37
Named foreign suppliers
6
Top origins
Germany · United Kingdom · Belgium

Shared foreign counterparties do not establish that these companies buy from Eisai.
What this tells a buyer
Eisai received 37 recorded shipments, predominantly sourced from Delpharm Huningue in France (18 shipments), internal manufacturing in the United Kingdom (9 shipments), and Siegfried Pharma in Switzerland (4 shipments), with goods also originating from Germany and Belgium.
The company operates research, development, and manufacturing operations across multiple locations, including facilities in Pennsylvania, Maryland, Hatfield England, and China, and develops targeted therapeutics such as monoclonal antibodies and antibody-drug conjugates.
Eisai is a private subsidiary of a publicly traded Japanese parent company and maintains a significant position in the North American pharmaceutical market with a portfolio addressing Alzheimer's disease, epilepsy, insomnia, and multiple cancer types.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
31 years in operation (founded 1995).
37 US import shipments on record.
Overview
Eisai Inc. is the North American pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., founded in 1995 and headquartered in Nutley, New Jersey. The company employs over 2,000 people and generates an estimated $5–10 billion in annual revenue. It discovers, develops, and markets therapies focused on neurology and oncology, serving the automotive, electric-vehicle, medical, renewable-energy, and industrial-equipment sectors. In 2026, Eisai extended a neurodegenerative disease research partnership with University College London and committed $64 million to expand its UK manufacturing facility for injectable drug packaging.
At a glance
Attribute | Detail |
|---|---|
Founded | 1995 |
Headquarters | Nutley, New Jersey |
Employees | 1,000-5,000 |
Revenue | $5-10B (estimated) |
Primary capability | Batteries & E-Mobility |
What Eisai makes
The company operates research, development, and manufacturing operations across multiple locations, including facilities in Pennsylvania, Maryland, Hatfield England, and China, and develops targeted therapeutics such as monoclonal antibodies and antibody-drug conjugates.
Trade and customs footprint
Eisai received 37 recorded shipments, predominantly sourced from Delpharm Huningue in France (18 shipments), internal manufacturing in the United Kingdom (9 shipments), and Siegfried Pharma in Switzerland (4 shipments), with goods also originating from Germany and Belgium. US customs bill-of-lading records list 37 inbound shipments across 6 foreign suppliers, with top origins including Germany · United Kingdom · Belgium.
Latest developments
2026-06-30 — Special UCL-Eisai neurodegenerative disease drug development partnership extended again | UCL News (ucl.ac.uk)
2026-06-15 — Japan's Eisai to pump $64m into UK plant to package injectable drugs - Nikkei Asia (nikkei.com)
2026-06-15 — Eisai claims UK grant to expand manufacturing site | pharmaphorum (pharmaphorum.com)
2026-02-05 — Henlius (henlius.com)
2026-01-12 — Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan (businesswire.com)
2025-09-12 — Eisai Celebrates New State-of-the-Art Manufacturing Facility in Baltimore (eisai.com)
Facilities
Eisai is headquartered in Nutley, New Jersey. Public sources also reference these locations:
Hatfield, England — nikkei.com
China — eisai.com.cn
Company details
Eisai is a private subsidiary of a publicly traded Japanese parent company and maintains a significant position in the North American pharmaceutical market with a portfolio addressing Alzheimer's disease, epilepsy, insomnia, and multiple cancer types. Eisai was founded in 1995, has an estimated 1,000-5,000 employees, and is headquartered in Nutley, New Jersey. On the LightSource stability read it is rated "Established & active": 31 years in operation (founded 1995). 37 US import shipments on record.
Frequently asked questions
What does Eisai make?
Eisai Inc. is the North American pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., founded in 1995 and headquartered in Nutley, New Jersey. The company employs over 2,000 people and generates an estimated $5–10 billion in annual revenue. It discovers, develops, and markets therapies focused on neurology and oncology, serving the automotive, electric-vehicle, medical, renewable-energy, and industrial-equipment sectors. In 2026, Eisai extended a neurodegenerative disease research partnership with University College London and committed $64 million to expand its UK manufacturing facility for injectable drug packaging.
Where is Eisai headquartered?
Eisai is headquartered in Nutley, New Jersey (200 Metro Blvd, Nutley, New Jersey, 07110-6102).
When was Eisai founded?
Eisai was founded in 1995.
How big is Eisai?
Eisai has an estimated 1,000-5,000 employees, with revenue in the $5-10B range (estimated).
Does Eisai import from overseas suppliers?
US customs bill-of-lading records show 37 inbound shipments for Eisai, with top origins including Germany · United Kingdom · Belgium.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
